搜索结果：Multiple sclerosis journal - experimental, translational and clinical

The novel data analytical platform General Effect Modelling (GEM), is an umbrella platform covering different data analytical methods that handle data with multiple design variables (or pseudo design variables) and multivariate responses. GEM is here demonstrated in an analysis of proteome data from cerebrospinal fluid (CSF) from two independent previously published datasets, one data set comprised of persons with relapsing-remitting multiple sclerosis, persons with other neurological disorders and persons without neurological disorders, and one data set had persons with clinically isolated syndrome (CIS), which is the first clinical symptom of MS, and controls. The primary aim of the present publication is to use these data to demonstrate how patient stratification can be utilised by GEM for multivariate analysis. We also emphasize how the findings shed light on important aspects of the molecular mechanism of MS that may otherwise be lost. We identified proteins involved in neural development as significantly lower for MS/CIS than for their respective controls. This information was only seen after stratification of the persons into two groups, which were found to have different in

Background: An early diagnosis together with an accurate disease progression monitoring of multiple sclerosis is an important component of successful disease management. Prior studies have established that multiple sclerosis is correlated with speech discrepancies. Early research using objective acoustic measurements has discovered measurable dysarthria. Objective: To determine the potential clinical utility of machine learning and deep learning/AI approaches for the aiding of diagnosis, biomarker extraction and progression monitoring of multiple sclerosis using speech recordings. Methods: A corpus of 65 MS-positive and 66 healthy individuals reading the same text aloud was used for targeted acoustic feature extraction utilizing automatic phoneme segmentation. A series of binary classification models was trained, tuned, and evaluated regarding their Accuracy and area-under-curve. Results: The Random Forest model performed best, achieving an Accuracy of 0.82 on the validation dataset and an area-under-curve of 0.76 across 5 k-fold cycles on the training dataset. 5 out of 7 acoustic features were statistically significant. Conclusion: Machine learning and artificial intelligence in a

Prognosis on the occurrence of relapses in individuals with Relapsing-Remitting Multiple Sclerosis (RRMS), the most common subtype of Multiple Sclerosis (MS), could support individualized decisions and disease management and could be helpful for efficiently selecting patients in future randomized clinical trials. There are only three previously published prognostic models on this, all of them with important methodological shortcomings. We aim to present the development, internal validation, and evaluation of the potential clinical benefit of a prognostic model for relapses for individuals with RRMS using real world data. We followed seven steps to develop and validate the prognostic model. Finally, we evaluated the potential clinical benefit of the developed prognostic model using decision curve analysis. We selected eight baseline prognostic factors: age, sex, prior MS treatment, months since last relapse, disease duration, number of prior relapses, expanded disability status scale (EDSS), and gadolinium enhanced lesions. We also developed a web application where the personalized probabilities to relapse within two years are calculated automatically. The optimism-corrected c-stati

Long-running clinical trials offer a unique opportunity to study disease progression and treatment response over time, enabling questions about how and when interventions alter patient trajectories. However, drawing causal conclusions in this setting is challenging due to irregular follow-up, individual-level heterogeneity, and time-varying confounding. Bayesian Additive Regression Trees (BART) and their extension, Bayesian Causal Forests (BCF), have proven powerful for flexible causal inference in observational data, especially for heterogeneous treatment effects and non-linear outcome surfaces. Yet, both models assume independence across observations and are fundamentally limited in their ability to model within-individual correlation over time. This limits their use in real-world longitudinal settings where repeated measures are the norm. Motivated by the NO.MS dataset, the largest and most comprehensive clinical trial dataset in Multiple Sclerosis (MS), with more than 35,000 patients and up to 15 years follow-up, we develop BCFLong, a hierarchical model that preserves BART's strengths while extending it for longitudinal analysis. Inspired by BCF, we decompose the mean into prog

Background: Digital health technologies allow for frequent, remote gait monitoring in people with multiple sclerosis (MS). However, to differentiate daily variability from actual disease progression in longitudinal data, established minimal clinically important differences (MCID) are required. Currently, there is limited literature defining these thresholds for digital gait metrics. Objective: To establish MCIDs for digital gait measures reflecting progression in MS. Methods: Digital gait measures were captured via daily, remote, smartphone-based Two-Minute Walk Tests in CONSONANCE (NCT03523858), a phase 3b study of ocrelizumab in progressive MS. Using an anchor-based approach, median changes from baseline at Week 96 on digital gait measures were computed for patients showing clinically meaningful worsening on either Timed 25-Foot Walk, Ambulation Score, Expanded Disability Status Scale, or 12-item Multiple Sclerosis Walking Scale. These changes were subsequently triangulated to derive the MCID estimates. Results: 243 patients with progressive MS (female: n=125 (51%); mean [SD] age: 49.3 [9.3]; mean [SD] EDSS: 4.8 [1.4]) had digital gait data available at baseline and Week 96. Medi

Multiple sclerosis is a neurological disorder in which the myelin sheaths of axons are damaged by the immune response. We report here a three-dimensional structural analysis of brain and spinal cord tissues of a mouse model of multiple sclerosis, known as experimental autoimmune encephalomyelitis (EAE). EAE-induced mice were raised with or without administration of fingolimod, which is used in the treatment of multiple sclerosis. Brains and spinal cords dissected from the EAE mice were lyophilized so as to reconstitute the intrinsic contrast of tissue elements, such as axons, in X-ray images. Three-dimensional structures of the brain hemispheres and spinal cords of the EAE mice were visualized with synchrotron radiation microtomography. Microtomographic cross sections reconstructed from the X-ray images revealed dilation of capillary vessels and vacuolation in the spinal cord of the EAE mice. Vacuolation was also observed in the cerebellum, suggesting that the neuroinflammatory response progressed in the brain. The vessel networks and vacuolation lesions in the spinal cords were modelled by automatically tracing the three-dimensional image in order to analyze the tissue structures

Background: Multiple Sclerosis (MS), an autoimmune disease affecting millions worldwide, is characterized by its variable course, in which some patients will experience a more benign disease course and others a more active one, with the latter leading to permanent neural damage and disability. Methods: This study uses a Markov Chain model to demonstrate the probability of movement across different states on the Expanded Disability Status Scale (EDSS) and attempted to define worsening, improvement, cycling, and stability of these different pathways. Most importantly we were interested in assessing the lack of impermanence of confirmed disability worsening and if it could be estimated from the Markov model. Results: The study identified only 8.1% were considered worsening, 5.6% consistent improving and 86% cyclers and less than 1% consistently stable. More importantly we also found that many (approximately 30%) of participants with confirmed disability worsening (CDW) regressed to stages that were not considered worsening, on subsequent visits after CDW. Conclusions: These finding are similar to what has been reported previously as predictors of worsening, and also for a lack of dura

Literature on machine learning for multiple sclerosis has primarily focused on the use of neuroimaging data such as magnetic resonance imaging and clinical laboratory tests for disease identification. However, studies have shown that these modalities are not consistent with disease activity such as symptoms or disease progression. Furthermore, the cost of collecting data from these modalities is high, leading to scarce evaluations. In this work, we used multi-dimensional, affordable, physical and smartphone-based performance outcome measures (POM) in conjunction with demographic data to predict multiple sclerosis disease progression. We performed a rigorous benchmarking exercise on two datasets and present results across 13 clinically actionable prediction endpoints and 6 machine learning models. To the best of our knowledge, our results are the first to show that it is possible to predict disease progression using POMs and demographic data in the context of both clinical trials and smartphone-base studies by using two datasets. Moreover, we investigate our models to understand the impact of different POMs and demographics on model performance through feature ablation studies. We a

Accurately measuring the evolution of Multiple Sclerosis (MS) with magnetic resonance imaging (MRI) critically informs understanding of disease progression and helps to direct therapeutic strategy. Deep learning models have shown promise for automatically segmenting MS lesions, but the scarcity of accurately annotated data hinders progress in this area. Obtaining sufficient data from a single clinical site is challenging and does not address the heterogeneous need for model robustness. Conversely, the collection of data from multiple sites introduces data privacy concerns and potential label noise due to varying annotation standards. To address this dilemma, we explore the use of the federated learning framework while considering label noise. Our approach enables collaboration among multiple clinical sites without compromising data privacy under a federated learning paradigm that incorporates a noise-robust training strategy based on label correction. Specifically, we introduce a Decoupled Hard Label Correction (DHLC) strategy that considers the imbalanced distribution and fuzzy boundaries of MS lesions, enabling the correction of false annotations based on prediction confidence. W

Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous system, characterized by the appearance of focal lesions in the white and gray matter that topographically correlate with an individual patient's neurological symptoms and signs. Magnetic resonance imaging (MRI) provides detailed in-vivo structural information, permitting the quantification and categorization of MS lesions that critically inform disease management. Traditionally, MS lesions have been manually annotated on 2D MRI slices, a process that is inefficient and prone to inter-/intra-observer errors. Recently, automated statistical imaging analysis techniques have been proposed to detect and segment MS lesions based on MRI voxel intensity. However, their effectiveness is limited by the heterogeneity of both MRI data acquisition techniques and the appearance of MS lesions. By learning complex lesion representations directly from images, deep learning techniques have achieved remarkable breakthroughs in the MS lesion segmentation task. Here, we provide a comprehensive review of state-of-the-art automatic statistical and deep-learning MS segmentation methods and discuss current an

In this study we investigate the Percolation Hypothesis for Multiple Sclerosis Progression. The methodology relies on cross-reference analysis centered around a question: What is the evidence for a Percolation/phase-transition hypothesis in Multiple Sclerosis (MS), especially the idea that the RRMS dynamic balance can abruptly break akin to crossing a percolation threshold into SPMS? We identify theoretical models invoking percolation/critical thresholds, network/connectome studies assessing percolation robustness or threshold-like behavior, clinical markers showing thresholds or early-warning signals, and counter-evidence arguing for gradual/continuum transitions.

The competency of any intelligent agent is bounded by its formal account of the world in which it operates. Clinical AI lacks such an account. Existing frameworks address evaluation, regulation, or system design in isolation, without a shared model of the clinical world to connect them. We introduce the Clinical World Model, a framework that formalizes care as a tripartite interaction among Patient, Provider, and Ecosystem. To formalize how any agent, whether human or artificial, transforms information into clinical action, we develop parallel decision-making architectures for providers, patients, and AI agents, grounded in validated principles of clinical cognition. The Clinical AI Skill-Mix operationalizes competency through eight dimensions. Five define the clinical competency space (condition, phase, care setting, provider role, and task) and three specify how AI engages human reasoning (assigned authority, agent facing, and anchoring layer). The combinatorial product of these dimensions yields a space of billions of distinct competency coordinates. A central structural implication is that validation within one coordinate provides minimal evidence for performance in another, re

This report summarizes the outcomes of the ICPR 2024 Competition on Multiple Sclerosis Lesion Segmentation (MSLesSeg). The competition aimed to develop methods capable of automatically segmenting multiple sclerosis lesions in MRI scans. Participants were provided with a novel annotated dataset comprising a heterogeneous cohort of MS patients, featuring both baseline and follow-up MRI scans acquired at different hospitals. MSLesSeg focuses on developing algorithms that can independently segment multiple sclerosis lesions of an unexamined cohort of patients. This segmentation approach aims to overcome current benchmarks by eliminating user interaction and ensuring robust lesion detection at different timepoints, encouraging innovation and promoting methodological advances.

Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system. Understanding multiple sclerosis progression and identifying the implicated brain structures is crucial for personalized treatment decisions. Deformation-based morphometry utilizes anatomical magnetic resonance imaging to quantitatively assess volumetric brain changes at the voxel level, providing insight into how each brain region contributes to clinical progression with regards to neurodegeneration. Utilizing such voxel-level data from a relapsing multiple sclerosis clinical trial, we extend a model-agnostic feature importance metric to identify a robust and predictive feature set that corresponds to clinical progression. These features correspond to brain regions that are clinically meaningful in MS disease research, demonstrating their scientific relevance. When used to predict progression using classical survival models and 3D convolutional neural networks, the identified regions led to the best-performing models, demonstrating their prognostic strength. We also find that these features generalize well to other definitions of clinical progression and can compensate for the omission of h

Developing AI models that are useful in clinical practice, requires efficient collaboration between clinicians and AI developers. This poses a practical challenge: clinicians must repeatedly communicate and refine their requirements with AI developers before those requirements can be translated into executable model development. This iterative process is time-consuming, and even after repeated discussion, misalignment may still exist because the two sides do not fully share each other's expertise. Coding agents may help close this gap. They can write and refine code on their own, and they carry working knowledge of both medicine and AI to understand commands formulated by both medical experts and developers. We present a prototype that lets clinicians drive AI development directly. A clinician describes the task in plain language, and the system turns the description into a working pipeline, refines it through repeated experiments together with the clinician, and returns a model that meets the stated clinical objective. Across five clinical tasks, the system reliably produces models that matched the clinician's request and reached competitive performance. Most notably, on chest rad

We compare the network of aggregated journal-journal citation relations provided by the Journal Citation Reports (JCR) 2012 of the Science and Social Science Citation Indexes (SCI and SSCI) with similar data based on Scopus 2012. First, global maps were developed for the two sets separately; sets of documents can then be compared using overlays to both maps. Using fuzzy-string matching and ISSN numbers, we were able to match 10,524 journal names between the two sets; that is, 96.4% of the 10,936 journals contained in JCR or 51.2% of the 20,554 journals covered by Scopus. Network analysis was then pursued on the set of journals shared between the two databases and the two sets of unique journals. Citations among the shared journals are more comprehensively covered in JCR than Scopus, so the network in JCR is denser and more connected than in Scopus. The ranking of shared journals in terms of indegree (that is, numbers of citing journals) or total citations is similar in both databases overall (Spearman's \r{ho} > 0.97), but some individual journals rank very differently. Journals that are unique to Scopus seem to be less important--they are citing shared journals rather than bein

Multiple Sclerosis (MS) is a chronic, inflammatory and degenerative neurological disease, which is monitored by a specialist using the Expanded Disability Status Scale (EDSS) and recorded in unstructured text in the form of a neurology consult note. An EDSS measurement contains an overall "EDSS" score and several functional subscores. Typically, expert knowledge is required to interpret consult notes and generate these scores. Previous approaches used limited context length Word2Vec embeddings and keyword searches to predict scores given a consult note, but often failed when scores were not explicitly stated. In this work, we present MS-BERT, the first publicly available transformer model trained on real clinical data other than MIMIC. Next, we present MSBC, a classifier that applies MS-BERT to generate embeddings and predict EDSS and functional subscores. Lastly, we explore combining MSBC with other models through the use of Snorkel to generate scores for unlabelled consult notes. MSBC achieves state-of-the-art performance on all metrics and prediction tasks and outperforms the models generated from the Snorkel ensemble. We improve Macro-F1 by 0.12 (to 0.88) for predicting EDSS an

Magnetic resonance imaging (MRI) plays a vital role in the scientific investigation and clinical management of multiple sclerosis. Analyses of binary multiple sclerosis lesion maps are typically "mass univariate" and conducted with standard linear models that are ill suited to the binary nature of the data and ignore the spatial dependence between nearby voxels (volume elements). Smoothing the lesion maps does not entirely eliminate the non-Gaussian nature of the data and requires an arbitrary choice of the smoothing parameter. Here we present a Bayesian spatial model to accurately model binary lesion maps and to determine if there is spatial dependence between lesion location and subject specific covariates such as MS subtype, age, gender, disease duration and disease severity measures. We apply our model to binary lesion maps derived from $T_2$-weighted MRI images from 250 multiple sclerosis patients classified into five clinical subtypes, and demonstrate unique modeling and predictive capabilities over existing methods.

We introduce Clinical ModernBERT, a transformer based encoder pretrained on large scale biomedical literature, clinical notes, and medical ontologies, incorporating PubMed abstracts, MIMIC IV clinical data, and medical codes with their textual descriptions. Building on ModernBERT the current state of the art natural language text encoder featuring architectural upgrades such as rotary positional embeddings (RoPE), Flash Attention, and extended context length up to 8,192 tokens our model adapts these innovations specifically for biomedical and clinical domains. Clinical ModernBERT excels at producing semantically rich representations tailored for long context tasks. We validate this both by analyzing its pretrained weights and through empirical evaluation on a comprehensive suite of clinical NLP benchmarks.